Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Studies muscle health in people with lung cancer during treatment

Checks whether muscle mass and strength relate to treatment tolerance in lung cancer patients.

Plain-language title generated from the registry record
Registry title: Sarcopenia and Cachexia in Patients With Lung Cancer

Key facts

Where
Næstved, DenmarkSee the site

Where in Denmark

  • Zealand University HospitalNæstved, DenmarkNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Zealand University Hospital
Trial code
NCT06730685
Record updated
12 February 2026
Original description
The PHILICA study investigates whether muscle mass, muscle strength, and muscle function are associated with treatment tolerance, quality of life and survival in patients with lung cancer. It also aims to explore why some patients face challenges in completing their treatment. The findings may contribute to improved strategies for supporting patients and developing more precise and individualized treatment plans in the future.Read full original descriptionShow less

PHILUCA: The Development of Muscle Mass, Muscle Strength, and Muscle Function in Patients With Lung Cancer During Cancer Treatment

The PHILICA study investigates whether muscle mass, muscle strength, and muscle function are associated with treatment tolerance, quality of life and survival in patients with lung cancer. It also aims to explore why some patients face challenges in completing their treatment. The findings may contribute to improved strategies for supporting patients and developing more precise and individualized treatment plans in the future.

Inclusion: Age ≥ 18 years of age; Diagnosed with lung cancer (all types and stages) and scheduled for oncological treatment; More than 3 months expected survival.

Exclusion: Competing cancer; Pregnancy; Severe physical or cognitive disabilities preventing physical testing and informend consent; Not able to read and understand Danish.

ClinicalTrials.gov NCT06730685